Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated Type 2 Diabetes Mellitus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Xijing Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Xijing Hospital
ClinicalTrials.gov Identifier:
NCT01372852
First received: June 11, 2011
Last updated: June 13, 2011
Last verified: May 2010
  Purpose

The objective of present study were to compare plasma adiponectin isoform status, their bioactivities newly diagnosed Chinese with healthy volunteer.


Condition
Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated T2DM Patients in Chinese Population

Resource links provided by NLM:


Further study details as provided by Xijing Hospital:

Primary Outcome Measures:
  • plasma adiponectin concentration, isoform distribution and activity. [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 week ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

blood,abdominal fat tissue


Estimated Enrollment: 300
Study Start Date: May 2010
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
T2DM patients
newly diagnosed T2DM patients and untreated with any drugs.
Non-diabetic Control Group

Detailed Description:

Adiponectin, circulates as trimer, hexamer and high molecular weight form (HMW) in human blood, is a promising biomarker for indication diabetes and cardiovascular disease. Both adiponectin complexes concentration and their bioactivities are decreased in pathological state. Disulfide-bond A oxidoreductase-like protein (DsbA-L) is a key regulator for adiponectin biosynthesis and its expression level is down-regulated in obese mice and humans. However, the alteration of circulating adiponectin multimers distribution, their bioactivities and adiponectin regulator, DsbA-L level, in newly diagnosed Chinese type 2 diabetes patients are unknown. The objective of present study were to compare plasma adiponectin isoform status, their bioactivities and DsbA-L concentration in newly diagnosed Chinese with healthy volunteer.

  Eligibility

Ages Eligible for Study:   30 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

This study enrolls a group of 30-70years patients from primary care clinic who have diabetes history within 12 months and without taking any treatment.

Criteria

Inclusion Criteria:

  • Having a diabetic history within 12 months
  • BMI smaller than 30kg/m2

Exclusion Criteria:

  • Having any kinds of treatment affecting glucose
  • pregnant
  • uncontrolled hypertension, active cardiac disease, or other major liver, kidney disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01372852

Contacts
Contact: Ling Tao, M.D Ph.D +86-15002955798 lingtao2006@gmail.com

Locations
China, Shaanxi
Xijing Hospital Recruiting
Xi'an, Shaanxi, China, 710032
Contact: Ling Tao, MD,PhD    +86-15002955798    lingtao2006@gmail.com   
Sponsors and Collaborators
Xijing Hospital
Investigators
Principal Investigator: Ling Tao, M.D Ph.D Department of Cardiology of Xijing Hospital, Fourth Military Medical University
  More Information

No publications provided

Responsible Party: Ling Tao, Department of Cardiology of Xijing Hospital; Fourth Military Medical University
ClinicalTrials.gov Identifier: NCT01372852     History of Changes
Other Study ID Numbers: xjyy110501
Study First Received: June 11, 2011
Last Updated: June 13, 2011
Health Authority: China: Food and Drug Administration

Keywords provided by Xijing Hospital:
Diabetes mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 24, 2014